Literature DB >> 9765347

F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.

W Koek1, J F Patoiseau, M B Assié, C Cosi, M S Kleven, E Dupont-Passelaigue, E Carilla-Durand, C Palmier, J P Valentin, G John, P J Pauwels, J P Tarayre, F C Colpaert.   

Abstract

F 11440 (4-methyl-2-[4-(4-(pyrimidin-2-yl)-piperazino)-butyl]-2H, 4H-1,2,4-triazin-3,5-dione) was the outcome of a research effort guided by the hypothesis that the magnitude of the intrinsic activity of agonists at 5-HT1A receptors determines the magnitude of their antidepressant and anxiolytic-like effects. The affinity of F 11440 for 5-HT1A binding sites (pKi, 8.33) was higher than that of buspirone (pKi, 7.50), and somewhat lower than that of flesinoxan (pKi, 8.91). In vivo, F 11440 was 4- to 20-fold more potent than flesinoxan, and 30- to 60-fold more potent than buspirone, in exerting 5-HT1A agonist activity at pre- and postsynaptic receptors in rats (measured by, for example, its ability to decrease hippocampal extracellular serotonin (5-HT) levels and to increase plasma corticosterone levels, respectively). F 11440 did not have detectable antidopaminergic activity (unlike buspirone, which inhibited all of the directly observable behavioral effects of methylphenidate in rats), showed no evidence of antihistaminergic activity (unlike flesinoxan, which protected against the effects of a histamine aerosol in guinea pigs), and had a 70-fold separation between its 5-HT1A agonist and alpha-1 adrenergic antagonist properties (measured as the ability to inhibit the methoxamineinduced increase in blood pressure in rats), unlike flesinoxan, which showed a <3-fold separation. In HeLa cells expressing human 5-HT1A receptors, F 11440 decreased the forskolin-induced increase in AMP, and, based on its maximal effect, was found to have an intrinsic activity of 1.0 relative to that of 5-HT, which was significantly higher than that of buspirone (0.49), ipsapirone (0.46) and flesinoxan (0.93). Consistent with the aforementioned hypothesis, F 11440 produced anxiolytic- and antidepressant-like effects in animal models (i.e., increased punished responding in a pigeon conflict procedure and decreased immobility in a rat forced swimming test, respectively) that were more substantial than those of buspirone, ipsapirone and flesinoxan. Thus, F 11440, shown here to be a potent, selective, high efficacy 5-HT1A receptor agonist, appears to have the potential to exert marked anxiolytic and antidepressant activity in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765347

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Dizziness produced by a potent 5HT(1A) receptor agonist (eptapirone) is not due to postural hypotension.

Authors:  S J Wilson; J E Bailey; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

2.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors:  R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 3.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

4.  Anxiolytic-like actions of buspirone in a runway model of intravenous cocaine self-administration.

Authors:  Aaron Ettenberg; Rick E Bernardi
Journal:  Pharmacol Biochem Behav       Date:  2006-10-24       Impact factor: 3.533

5.  Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat.

Authors:  M-B Assié; H Lomenech; V Ravailhe; V Faucillon; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2006-08-14       Impact factor: 8.739

Review 6.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Effects of buspirone on the immediate positive and delayed negative properties of intravenous cocaine as measured in the conditioned place preference test.

Authors:  Aaron Ettenberg; Rick E Bernardi
Journal:  Pharmacol Biochem Behav       Date:  2007-05-04       Impact factor: 3.533

9.  Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist.

Authors:  A Newman-Tancredi; J-C Martel; M-B Assié; J Buritova; E Lauressergues; C Cosi; P Heusler; L Bruins Slot; F C Colpaert; B Vacher; D Cussac
Journal:  Br J Pharmacol       Date:  2009-01-12       Impact factor: 8.739

10.  Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model

Authors:  Adam Pettitt
Journal:  eNeuro       Date:  2015-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.